| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Mark B. McClellan is Director at ALHC and has filed Form 4s across 2 companies. Mark B. McClellan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.8M at current prices.
The biggest single holding is ALHC (~$2.7M) as Director. The ALHC filings lean toward selling, a net 19,603 shares.
Mark B. McClellan has 35 Form 4 filings on record from February 2018 to April 2026, across 3 companies: Director at Johnson & Johnson (JNJ), 2018–2026; Director at The Cigna Group (CI), 2018–2026; Director at Alignment Healthcare (ALHC), 2021–2026.
The 36 reported transactions were 25 stock awards, 9 option or other derivative awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $354K.
The largest open-market sale was 12,103 shares of ALHC at an average $16.83 on April 6, 2021, about $204K. Twelve months later ALHC was down 52%.